Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

Bingshe Han, Dongkyoo Park, Rui Li, Maohua Xie, Taofeek K. Owonikoko, Guojing Zhang, Gabriel L. Sica, Chunyong Ding, Jia Zhou, Andrew T. Magis, Zhuo G. Chen, Dong M. Shin, Suresh S. Ramalingam, Fadlo R. Khuri, Walter J. Curran, Xingming Deng

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer invivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.

Original languageEnglish (US)
Pages (from-to)852-863
Number of pages12
JournalCancer Cell
Volume27
Issue number6
DOIs
StatePublished - Jun 8 2015

Fingerprint

Lung Neoplasms
Therapeutics
Heterografts
Cell Death
Up-Regulation
Clinical Trials
Cell Line
Survival
BDA-366
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Han, B., Park, D., Li, R., Xie, M., Owonikoko, T. K., Zhang, G., ... Deng, X. (2015). Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell, 27(6), 852-863. https://doi.org/10.1016/j.ccell.2015.04.010

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. / Han, Bingshe; Park, Dongkyoo; Li, Rui; Xie, Maohua; Owonikoko, Taofeek K.; Zhang, Guojing; Sica, Gabriel L.; Ding, Chunyong; Zhou, Jia; Magis, Andrew T.; Chen, Zhuo G.; Shin, Dong M.; Ramalingam, Suresh S.; Khuri, Fadlo R.; Curran, Walter J.; Deng, Xingming.

In: Cancer Cell, Vol. 27, No. 6, 08.06.2015, p. 852-863.

Research output: Contribution to journalArticle

Han, B, Park, D, Li, R, Xie, M, Owonikoko, TK, Zhang, G, Sica, GL, Ding, C, Zhou, J, Magis, AT, Chen, ZG, Shin, DM, Ramalingam, SS, Khuri, FR, Curran, WJ & Deng, X 2015, 'Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy', Cancer Cell, vol. 27, no. 6, pp. 852-863. https://doi.org/10.1016/j.ccell.2015.04.010
Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015 Jun 8;27(6):852-863. https://doi.org/10.1016/j.ccell.2015.04.010
Han, Bingshe ; Park, Dongkyoo ; Li, Rui ; Xie, Maohua ; Owonikoko, Taofeek K. ; Zhang, Guojing ; Sica, Gabriel L. ; Ding, Chunyong ; Zhou, Jia ; Magis, Andrew T. ; Chen, Zhuo G. ; Shin, Dong M. ; Ramalingam, Suresh S. ; Khuri, Fadlo R. ; Curran, Walter J. ; Deng, Xingming. / Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. In: Cancer Cell. 2015 ; Vol. 27, No. 6. pp. 852-863.
@article{29061a9565b34710a16c66db22106e9f,
title = "Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy",
abstract = "The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer invivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.",
author = "Bingshe Han and Dongkyoo Park and Rui Li and Maohua Xie and Owonikoko, {Taofeek K.} and Guojing Zhang and Sica, {Gabriel L.} and Chunyong Ding and Jia Zhou and Magis, {Andrew T.} and Chen, {Zhuo G.} and Shin, {Dong M.} and Ramalingam, {Suresh S.} and Khuri, {Fadlo R.} and Curran, {Walter J.} and Xingming Deng",
year = "2015",
month = "6",
day = "8",
doi = "10.1016/j.ccell.2015.04.010",
language = "English (US)",
volume = "27",
pages = "852--863",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

AU - Han, Bingshe

AU - Park, Dongkyoo

AU - Li, Rui

AU - Xie, Maohua

AU - Owonikoko, Taofeek K.

AU - Zhang, Guojing

AU - Sica, Gabriel L.

AU - Ding, Chunyong

AU - Zhou, Jia

AU - Magis, Andrew T.

AU - Chen, Zhuo G.

AU - Shin, Dong M.

AU - Ramalingam, Suresh S.

AU - Khuri, Fadlo R.

AU - Curran, Walter J.

AU - Deng, Xingming

PY - 2015/6/8

Y1 - 2015/6/8

N2 - The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer invivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.

AB - The BH4 domain of Bcl2 is required for its antiapoptotic function, thus constituting a promising anticancer target. We identified a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer invivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome.

UR - http://www.scopus.com/inward/record.url?scp=84930573524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930573524&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.04.010

DO - 10.1016/j.ccell.2015.04.010

M3 - Article

C2 - 26004684

AN - SCOPUS:84930573524

VL - 27

SP - 852

EP - 863

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -